The way I see it ORMP worth as much as currently $250ml on a buyout . They are 5yrs closer to market than comp.
Novo the leader in diabetic pharma.spends billions on R&D. They would not buy ORMP and scrap their current product under development . They will buy ORMP and bring to market because ORMP ahead of them . Depending on what they have in their own product it would either be combo or be brought up the latter as the next generation oral insulin. Either way ORMP in trials and in first to market advantage and may be best product under development . Novo could spend $500ml to $1bl to get what they have where ORMP currently is.
I agree! There is no way they would sell for that offer. This is 30 years of research which wont be thrown away to first bidders. The interviews given by Kidron he continuously talks about partnering with big pharma, as late as yesterday! They are not after a quick buck they want to create something major from mother to son. All in my opinion. Glta
Yes but ORMP ahead and NOVO owns diabetic market,That is why I spoke of NOvo acquiring and develop both bring theirs out as next generation after capturing market with ORMP product or a combination there of. Oral insulin is a $18bl+ annually market.ORMP is small enough buyout would be more likely than partnering I think.